Ingrid Oakley-Girvan, Ph.D., M.P.H.
Research Scientist, Northern California Cancer Center Consulting Assistant Professor, Division of Epidemiology, Dept. of Health Research & Policy, Stanford University School of Medicine Member, Stanford Cancer Center
2201 Walnut Avenue, Suite 300
Fremont, California 94538-2334 E-mail: ioakley@nccc.org Phone: 510-608-5045 Fax: 510-608-5085
Research Interests:
Evaluating factors associated with racial disparities in prostate cancer diagnosis, progression and survival
Evaluating genetic factors and gene/environment interactions involved in prostate cancer incidence, progression and survival
Evaluating genetic factors and gene/environment interactions involved in ovarian cancer incidence and survival
Assessing quality of life and survivorship issues two or more years after diagnosis
Dr. Oakley-Girvan's research concentrates on studies of breast, ovarian and prostate cancer with an emphasis on genetic epidemiology and survivorship.
Genetic epidemiology: Identifying genes that increase susceptibility to cancer or are related to poor survival is a primary interest of Dr. Oakley-Girvan. She is part of the International Consortium for Prostate Cancer Genetics and a member in an international breast and ovarian cancer research group. Through these collaborative teams, which include a broad base of investigators from many institutions and genetic samples from many projects, Dr. Oakley-Girvan is able to focus on investigating genes that may increase a person's susceptibility to prostate, ovarian and breast cancer. In addition, she aims to identify environmental factors that reduce an individual's risk of these cancers, as well as decrease their risk of cancer recurrence and improve their chance of survival.
Survivorship: Dr. Oakley-Girvan is also actively evaluating factors associated with cancer treatment choice, quality of care, treatment outcomes and quality of life. With interests throughout the cancer survivorship continuum and an emphasis on understanding why there are disparities in survivor care, Dr. Oakley-Girvan is also focused on creating solutions. She plans to follow her current studies with education and intervention projects that will effect meaningful change, improve the life of survivors and help eliminate, or, at the very least, reduce cancer health care disparities.
Zeliadt SB, Ramsey SD, Potosky AL, Arora NK, Blough DK, Oakley-Girvan I, Hamilton AS, Van Den Eeden SK, Penson DF. Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. The Patient: Patient-Centered Outcomes Research 2008; 1(3):189-200.
Beckjord EB, Arora NK, Mclaughlin W, Oakley-Girvan I, Hamilton AS, Hesse BW, Population-Based Assessment of Long-Term Survivors’ Information Needs: Implications for Cancer Care. Journal of Cancer Survivorship: Research and Practice, 2008.
Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak MD, Whittemore AS, Wu AH, Gallagher RP. Pre-diagnostic C-peptide and risk of prostate cancer. CEBP 2007; 16(10):2164-2165. (PMID: 17932367)
Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, Whittemore AS, Ponder BA, Piver MS, Pharoah PD, Gayther SA. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.Human Mutation 2007 Dec; 28(12):1207-15. [epub]. (PMID: 17688236)
Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Isaacs WB; International Consortium for Prostate Cancer Genetics. Compelling Evidence for a Prostate Cancer Gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet. 2007 Jun; 16(11):1271-8. [epub]. (
PMID: 17478474)
Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D.Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39(5):638-44. (PMID: 17401364)
Professional Memberships, Professional Activities, and Awards: 1997-2002 NCI Cancer Training Grant, Stanford University 1992 Cancer Association of New Orleans Student Research Grant 1992 Founders' Academic Scholarship, Zeta Tau Alpha Sorority 1991-1992 Deans' Grant, School of Public Health, Tulane University 1987 Order of Omega Honor Society, University of Michigan
